a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

NCT ID: NCT02846584

Last Updated: 2016-09-07

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2019-12-31

Brief Summary

The main purpose of this study is to explore the sequential therapeutic effect and evaluate the safety of anti-CD19 or anti-CD20 CAR-T cells briging HSCT in the treatment of relapse/refractory B cell malignancies.

Detailed Description

The CD19-targeted CAR-T has shown exellent therapeutic efficiency in B cell malignancies,especially in acute lymphocytic leukemia. Recently the anti-CD20 CAR T cells has been used in the treatment of relapsed/refractory DLBCL and exhibited good clinical outcomes.

However, patients treated with CAR-T may face relapse of CD19 or CD20 mutation. Therefore we attempt to maintain and relieve patients by sequential therapy of the HSCT and hope to combine their advantages.

Conditions

Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma，Malignant

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CD19 or CD20 CAR T cells briging HSCT

lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.

Group Type: EXPERIMENTAL

CD19 or CD20 CAR T cells briging HSCT

Intervention Type: BIOLOGICAL

Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.

Interventions

CD19 or CD20 CAR T cells briging HSCT

Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. CD19-expressing or CD20-expressing relapsed or refractory B cell malignancies after at least one standard chemotherapy and one salvage regimen.According to current traditional therapies, there must be no available alternative curative therapies.

2. Patients enrolled must have an evaluated score above 60 with KPS.

3. Expected survival time of patients enrolled is over 3 months.

4. Gender is not limited, age from 14 years to 75 years.

5. Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.

6. Adequate absolute CD3 count estimated need to be assured for obtaining target cell dose based on dosage cohorts.

7. Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)

8. Patients with isolated CNS relapse will be eligible if they have previously been treated with cranial radiation (at least 1800 cGy).

9. Ability to give informed consent.

10. Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.

11. Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.

12. Renal function: Creatinine level of peripheral blood is required no greater than 133umol/L.

13. Patients with history of allogeneic stem cell transplantation are eligible if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.

14. Patients volunteer to participate in the research.

Exclusion Criteria

• Subjects meeting any of the following criteria are not eligible for participation in the study:

1. Patients are evaluated below 50 scores with KPS.

2. Evident signs suggesting that patients are potentially allergic to cytokines.

3. Frequent infection history and recent infection is uncontrolled.

4. Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome

5. Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.

6. Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.

7. Pregnancy and nursing females. HIV infection.

8. Active hepatitis B or active hepatitis C.

9. Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed.

10. Class III/IV cardiovascular disability according to the New York Heart Association Classification.

11. Patients with a known history or prior diagnosis of other serious immunologic, malignant or inflammatory disease.

12. Other situations we think not eligible for participation in the research.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Southwest Hospital, China

OTHER

Sponsor Role: lead

Responsible Party

Jieping Chen

Head of Hematology Department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jieping Chen, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Southwest Hospital, China

Locations

Southwest Hospital of Third Millitary Medical University

Chongqing, Chongqing Municipality, China

Countries

China

Other Identifiers

Southwest Hospital，China

Identifier Type: -

Identifier Source: org_study_id